David P. Walsh
Founder & Chief Executive Officer
David Walsh founded DGP Life Science in 1998 after co-launching and running the dangerous goods packing company, Trident Safety Group for ten years. DGP Life Science developed a unique packaging solution designed for the transportation of samples suspected of containing the BSE (Bovine Spongiform Encephalitis, or “Mad Cow Disease”) prion. Within a year, Intelsius was supplying the first UN-certified BSE sample shipper in the world to a global client base. As the company expanded its products & service offerings it became widely recognized as one of the global market leaders of life sciences temperature control and healthcare regulatory-compliant packaging solutions.
Since then, Mr. Walsh built the DGP Headquarters and Research and Development Center in the United Kingdom and expanded its manufacturing facilities from the U.K. to the United States, Ireland, The Netherlands, India, and Malaysia. To reflect the focus and the growth of the life sciences packaging business, Mr. Walsh rebranded the life science packaging division in 2011 as Intelsius, A DGP Company.
Over the past decade, Mr. Walsh has elevated Intelsius to a highly respected global leader in the life sciences industry. He has maintained a dedication to environmentally sustainable product development that is unrivaled in the industry. Mr. Walsh is widely regarded as an expert in environmentally sustainable business practices and is often called upon to give presentations on the subject.
Mr. Walsh has extensive knowledge of clinical trial logistics, the pharmaceutical cold chain, dangerous goods legislation and compliance. The combination of skills and experience make him an invaluable asset both to Intelsius and its clients. His commitment to green solutions development sets him apart from traditional entrepreneurs.
Mr. Walsh was a presenter at a symposium of life sciences industry professionals in Shanghai, China and the Irish Exporters Association in Galway, Ireland. Mr. Walsh has many published articles to his credit; “The Impact of the GDP Guidelines on Design, Qualification and Validation of Packaging Systems” appeared in the December issue of the International Pharmaceutical Industry journal and “The Five Steps of Contingency Planning” was published in the November 2012 issue of Life Science Leader magazine.
In addition to his endeavors with Intelsius, Mr. Walsh is also the owner of a UK-based Green chemicals and veterinary infection control company, a product designer, an inventor and a medical device patent holder.
Pursuits and interests include sailing, skiing, golf, chess, fishing, travel, reading and film.